PUBLISHER: Grand View Research | PRODUCT CODE: 1321412
PUBLISHER: Grand View Research | PRODUCT CODE: 1321412
The global AV fistula devices market size is expected to reach USD 556.6 million by 2030, according to a new report by Grand View Research, Inc. The market is expected to grow at a CAGR of 7.6% from 2023 to 2030. AVFs are abnormal connections between arteries and veins, which can arise from congenital factors, trauma, or surgical procedures. These abnormal connections are frequently observed in both limbs and internal organs, including the liver and brain. In the context of healthcare, AVFs are deliberately established for patients suffering from End-stage Renal Disease (ESRD) who necessitate hemodialysis. By creating AVFs, healthcare providers can establish a dependable and enduring access point to the bloodstream for efficient dialysis treatments.
The market for arteriovenous fistula (AVF) devices is driven by several factors, including the rising prevalence of ESRD necessitating hemodialysis, where AVFs are created to provide reliable vascular access for dialysis treatments. In addition, advancements in minimally invasive procedures, such as endovascular techniques and embolization, have fueled the demand for AVF devices.
Key players are actively implementing strategic initiatives, including acquisitions, mergers, collaborations, and robust research and development activities, to enhance their market dominance. These initiatives aim to strengthen their product portfolios, expand their market presence, and drive innovation in AVF device technologies.
For instance, in May 2022 VentureMed Group completed the enrollment of a Randomized Controlled Trial (RCT) named 'Flex Vessel Prep before PTA for the treatment of obstructive lesions in the native AVF.' This clinical trial was designed to evaluate the primary patency at six months by utilizing the Flex Vessel Prep system before Percutaneous Transluminal Angioplasty (PTA), compared to PTA alone, for treating obstructive lesions in native AVFs in the upper extremity. Such research initiatives play a crucial role in generating clinical evidence and demonstrating the efficacy and safety of AVF devices.
Thus, as companies invest in research and development, the market can expect the introduction of innovative devices that enhance AVF patency, minimize complications, and provide superior solutions for patients with AVFs.